A brand running its own mineral sunscreen line hits a frustrating wall when in vitro SPF readings suddenly drop below the label claim, even though nothing in the recipe changed. For a product marketed with a protection cap tied to a specific SPF number, that kind of swing is not cosmetic, it affects whether the label claim and any related safety positioning can still be made at all.
This situation comes up more often with zinc-based mineral formulas than with chemical filters. High-zinc systems are typically dosed by weight, but in vitro testing applies a fixed amount per square centimeter of skin area. When a formula runs denser, closer to 1.3 to 1.7 g per ml, the same weight-based zinc load can spread thinner across the test area than expected, which drags the in vitro number down even though the formula itself did not change. It is a measurement artifact as much as a formulation one, but regulators and retailers do not care about the explanation if the paperwork does not support the claim on the tube.

One case involving an Australian brand producing roughly 500,000 body tubes a year ran into exactly this before shipment. Rather than reformulating blind, the manufacturing partner supplied the formula, raw material specs, and an in vivo SPF and UVA dossier under a licensing arrangement, while the brand kept blending, filling, and the country-of-origin labeling in house. That split let the brand keep its claim structure intact without taking on the testing and documentation burden itself, which is one argument for using an OEM or ODM partner like Guangzhou Yilong Cosmetics for documentation-heavy mineral formulas rather than running the whole chain internally.
Is it more common in practice to re-test and reformulate downward, or to challenge the in vitro reading with supporting in vivo data when zinc-heavy formulas test low?
http://www.yilongsuncare.com
Guangzhou Yilong Cosmetics Co., Ltd.